Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PROTACS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | PROTACS |
graph TD
PROTACS[PROTACS]
PROTACS -->|mediates| Intracellular_Protein_Degradat[Intracellular Protein Degradation]
PROTACS -->|activates| protein_degradation[protein degradation]
PROTACS -->|promotes| UBIQUITIN[UBIQUITIN]
PROTACS -->|promotes| ubiquitylation[ubiquitylation]
PROTACS -->|targets| Multimeric_Proteins[Multimeric Proteins]
PROTACS -->|targets| Disease_Associated_Proteins[Disease-Associated Proteins]
PROTACS -->|targets| BCL2[BCL2]
PROTACS -->|targets| ZFPs[ZFPs]
PROTACS -->|treats| Cancer[Cancer]
PROTACS -->|modulates| Zinc_Finger_Proteins[Zinc Finger Proteins]| Target | Relation | Type | Str |
|---|---|---|---|
| protein degradation | activates | process | 0.95 |
| Intracellular Protein Degradation | mediates | process | 0.95 |
| Multimeric Proteins | targets | protein | 0.90 |
| UBIQUITIN | promotes | protein | 0.90 |
| ubiquitylation | promotes | process | 0.90 |
| BCL2 | targets | protein | 0.85 |
| Disease-Associated Proteins | targets | protein | 0.85 |
| ZFPs | targets | protein | 0.85 |
| Cancer | treats | disease | 0.85 |
| Zinc Finger Proteins | modulates | protein | 0.80 |
| Cancer | treats | disease | 0.80 |
| BCL2 | targets | protein | 0.75 |
| Blood-Brain Barrier Impairment | treats | phenotype | 0.70 |
| BBB impairment | treats | phenotype | 0.65 |
| APOE4 | inhibits | protein | 0.50 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Selective APOE4 Degradation via Proteolysis Targeting Chimer | 0.795 | neurodegeneration | APOE4 structural biology and therapeutic |
| p21-Targeted Proteolysis-Targeting Chimeras (PROTACs) | 0.000 | - | Senolytic therapy for age-related neurod |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] | Zhu L, Du L, Wu J, Ding D, Wang J et al. | J Invest Dermatol | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
| Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] | Lin Z, Xiong J, Zhang F, Zhang H, Zhu M | Mol Ther | 2026 | 0 |
| Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] | Samudra N, Vemuri M, Weitlauf J | Curr Opin Obstet Gynecol | 2026 | 0 |
| Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pa [PMID:41930593] | Yoshida K, Saito N, Takahashi R, Ando S, | J Alzheimers Dis | 2026 | 0 |
| UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylati [PMID:41930933] | Ding SK | Immunol Invest | 2026 | 0 |
| Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disor [PMID:40145985] | Lozupone M, Leccisotti I, Mollica A, Ber | Neural regeneration research | 2026 | 0 |
| Cognitive Decline and Neurodegenerative Markers in Psoriasis: The Role of APOE4 [PMID:41912201] | Sabry HH, Kadhum BQ, Abdulmohsin GN, El- | Dermatology practical & concep | 2026 | 0 |
| Association of Periodontal Pathogens and Their Inflammatory Mediators With Alzhe [PMID:41890452] | Arriaga P, Vianna K, Montez C, Panariell | Cureus | 2026 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning PROTACS in their description or question text
No additional research found